Total Valuation
Enveric Biosciences has a market cap or net worth of €4.58M. The enterprise value is -€4.13M.
Market Cap€4.58M
Enterprise Value-€4.13M
Share Statistics
Enveric Biosciences has 3,681,884 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding3,681,884
Owned by Insiders16.62%
Owned by Institutions0.46%
Financial Efficiency
Enveric Biosciences’s return on equity (ROE) is -2.90 and return on invested capital (ROIC) is -210.04%.
Return on Equity (ROE)-2.90
Return on Assets (ROA)-2.38
Return on Invested Capital (ROIC)-210.04%
Return on Capital Employed (ROCE)-2.10
Revenue Per Employee0.00
Profits Per Employee-1.75M
Employee Count5
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Enveric Biosciences is ―. Enveric Biosciences’s PEG ratio is 0.00119.
PE Ratio―
PS Ratio0.00
PB Ratio0.29
Price to Fair Value0.29
Price to FCF-0.15
Price to Operating Cash Flow-0.27
PEG Ratio0.00119
Income Statement
In the last 12 months, Enveric Biosciences had revenue of 0.00 and earned -12.13M in profits. Earnings per share was -36.24.
Revenue0.00
Gross Profit-200.86K
Operating Income-8.77M
Pretax Income-8.77M
Net Income-12.13M
EBITDA-8.57M
Earnings Per Share (EPS)-36.24
Cash Flow
In the last 12 months, operating cash flow was -8.01M and capital expenditures -4.00, giving a free cash flow of -8.01M billion.
Operating Cash Flow-8.01M
Free Cash Flow-8.01M
Free Cash Flow per Share-2.17
Dividends & Yields
Enveric Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.84
52-Week Price Change0.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)0.00
Important Dates
Enveric Biosciences upcoming earnings date is Aug 17, 2026, Before Open (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Enveric Biosciences as a current ratio of 5.38, with Debt / Equity ratio of 0.00%
Current Ratio5.38
Quick Ratio5.38
Debt to Market Cap0.00
Net Debt to EBITDA0.55
Interest Coverage Ratio-82.78K
Taxes
In the past 12 months, Enveric Biosciences has paid 3.36M in taxes.
Income Tax3.36M
Effective Tax Rate-0.38
Enterprise Valuation
Enveric Biosciences EV to EBITDA ratio is 0.40, with an EV/FCF ratio of 0.43.
EV to Sales0.00
EV to EBITDA0.40
EV to Free Cash Flow0.43
EV to Operating Cash Flow0.43
Balance Sheet
Enveric Biosciences has €4.91M in cash and marketable securities with €0.00 in debt, giving a net cash position of €4.91M billion.
Cash & Marketable Securities€4.91M
Total Debt€0.00
Net Cash€4.91M
Net Cash Per Share€1.33
Tangible Book Value Per Share€12.48
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Enveric Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―